Get the Stockscreener App
29.96
0.70%
-0.21
After Hours:
29.96
Viking Therapeutics Inc Stock (VKTX) Latest News
$100 Invested In Viking Therapeutics 5 Years Ago Would Be Worth This Much Today - Benzinga
Why Viking Therapeutics Inc. (VKTX) Went Down on Monday - Insider Monkey
Why Hims & Hers Health Stock Crushed Novo Nordisk and Viking Therapeutics Today - The Motley Fool
Viking Therapeutics Stock Price Forecast for 2025 - Markets.com
Viking Therapeutics started at neutral by Citi - MSN
How to Take Advantage of moves in (VKTX) - Stock Traders Daily
VKTX's Q4 Loss Wider Than Expected, Sales Nil, Stock Down 10% - MSN
Viking Therapeutics price target lowered to $96 from $109 at B. Riley - Yahoo Finance
2 Stocks That Could Soar Again in 2025 - Yahoo Finance
Viking Therapeutics Stock Down Over 20% In 2025: Retail Traders Predict Where It Could End The Year - MSN
B. Riley Adjusts Price Target on Viking Therapeutics to $96 From $109, Keeps Buy Rating - Marketscreener.com
Citigroup Initiates Viking Therapeutics at Neutral With $38 Price Target -February 07, 2025 at 08:52 am EST - Marketscreener.com
Truist Securities Adjusts Viking Therapeutics Price Target to $95 From $120, Maintains Buy Rating - Marketscreener.com
Citigroup initiated coverage on Viking Therapeutics with a new price target - Quantisnow
Viking Therapeutics Reports Strong Trials and Financial Health - TipRanks
Viking Therapeutics Plunged 6% On Its Earnings Report. Here's Why. - Yahoo
Viking Therapeutics Reports Q4 2024 Financial Results, Advances VK2735 Trials - Yahoo Finance
Viking Therapeutics, Inc. (VKTX) Outpaces Stock Market Gains: What You Should Know - MSN
Has the Bubble Burst for Viking Therapeutics Stock? - MSN
Viking Therapeutics price target raised to $125 from $122 at Raymond James - TipRanks
Viking Therapeutics Inc (VKTX) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Rising ... - Yahoo Finance
Viking Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 - Marketscreener.com
Viking Therapeutics Reports Positive 2024 Financials and Clinical Progress - TipRanks
Viking Therapeutics Plummeted 10% On Its Earnings Report. Here's Why. - Yahoo! Voices
Viking Therapeutics targets Phase 3 trials for VK2735 in Q2 2025 amid strong clinical progress - MSN
Viking Therapeutics : February 2025 Corporate Presentation - Marketscreener.com
Viking Therapeutics Shares Drop After Q4 EPS Miss Estimates - Benzinga
Viking stock slides 8% following Q4 report, pipeline update - Seeking Alpha
Viking Therapeutics Reports Fourth Quarter and Year-End 2024 Fin - GuruFocus.com
Viking Therapeutics, Inc. (VKTX): One of January’s Biggest Losers - Insider Monkey
Viking Therapeutics reports Q4 EPS (32c), consensus (27c) - TipRanks
Viking's Obesity Drug Achieves 14.7% Weight Loss, Phase 3 Launch Set for Q2 - StockTitan
Viking Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update - Yahoo Finance
BlackRock, Inc. Expands Stake in Viking Therapeutics Inc - GuruFocus.com
Wall Street Analysts Think Viking Therapeutics (VKTX) Is a Good Investment: Is It? - MSN
Prediction: This Pharma Stock Will Be the Best Performer in 2025 - 24/7 Wall St.
Why Does Jim Cramer Prefer Eli Lilly (LLY) Over Viking Therapeutics? - MSN
Viking Therapeutics: Why The Oral VK2735 Phase 2 Readout Could Send The Stock Soaring - Seeking Alpha
Can Viking Touch The $100 Mark? - RTTNews
Viking Therapeutics, Inc. (NASDAQ:VKTX) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares Purchased by Janney Montgomery Scott LLC - MarketBeat
Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares Bought by U.S. Capital Wealth Advisors LLC - MarketBeat
Brokerages Set Viking Therapeutics, Inc. (NASDAQ:VKTX) PT at $106.75 - MarketBeat
Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares Bought by Institute for Wealth Management LLC. - MarketBeat
Viking Therapeutics (VKTX) to Release Quarterly Earnings on Wednesday - MarketBeat
Viking Therapeutics Stock Before Q4 Earnings: To Buy or Not to Buy? - MSN
This Weight Loss Stock Could Soar Over 220%, According to Wall Street. Time to Buy? - sharewise
Jim Cramer’s Take on Viking Therapeutics (VKTX): “Sell Viking Therapeutics and Roll it into Viking Holdings” - Insider Monkey
SG Americas Securities LLC Boosts Stock Position in Viking Therapeutics, Inc. (NASDAQ:VKTX) - MarketBeat
2.27%
5.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):